Ghorbani Zeinab, Shoaibinobarian Nargeskhatoon, Noormohammadi Morvarid, Taylor Kate, Kazemi Asma, Bonyad Ali, Khoshdooz Sara, Löber Ulrike, Forslund-Startceva Sofia K
Cardiovascular Diseases Research Center, Department of Cardiology, Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran; Department of Clinical Nutrition, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
Department of Clinical Nutrition, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran; Department of Nutrition, School of Medical Sciences and Technologies, Islamic Azad University, Science and Research Branch, Tehran, Iran.
Pharmacol Res. 2025 Jun;216:107780. doi: 10.1016/j.phrs.2025.107780. Epub 2025 May 15.
Given the magnitude and variety of chronic metabolic disease linked to increased intestinal permeability, appropriate strategies to reinforce gut barrier function are urgently needed.
This systematic review and meta-analysis explores the effects of pro- and synbiotic, or prebiotic administration, on various intestinal permeability markers. Systematic searches across the Medline and Scopus databases were performed from 1961 to January 2023. The review included data from 46 published studies on pro- and synbiotics, and 22 studies on prebiotics. 46 The meta-analysis calculated standardized mean differences (SMD) along with 95 % confidence intervals (95 %CIs) using a random-effects model to evaluate the average effect sizes (ES). To analyze heterogeneity, we employed Galbraith plots and performed the Cochrane Chi-squared test.
The analysis on 24 trials (28 ES, n = 1603) revealed a significant reduction in lipopolysaccharide levels following pro- and synbiotics consumption with high heterogeneity and very low certainty of evidence (SMD (95 %CI) = -0.54 (-1.01, -0.07); I (%) = 94.4). Synthesis of 13 trials showed zonulin levels were significantly lowered after pro- and synbiotics consumption with high heterogeneity and moderate certainty of evidence (15 ES, n=778) (SMD (95 %CI) = -0.49 (-0.79, -0.18); I (%) = 74.9). Following prebiotics supplementation, a significant reduction in lipopolysaccharide levels was observed, with high heterogeneity identified from data including 16 RCTs (n = 792; SMD (95 %CI) = -0.88 (-1.28, -0.47); P < 0.001; high certainty of evidence; I (%) = 85.7; P-heterogeneity< 0.001).
This meta-analysis revealed promising findings regarding the efficacy of pro- and synbiotic and prebiotic supplements in alleviating "leaky gut".
鉴于与肠道通透性增加相关的慢性代谢性疾病的规模和种类,迫切需要适当的策略来增强肠道屏障功能。
本系统评价和荟萃分析探讨了益生菌、合生元或益生元给药对各种肠道通透性标志物的影响。对1961年至2023年1月期间的Medline和Scopus数据库进行了系统检索。该评价纳入了46项已发表的关于益生菌和合生元的研究数据,以及22项关于益生元的研究数据。荟萃分析使用随机效应模型计算标准化平均差(SMD)以及95%置信区间(95%CI),以评估平均效应大小(ES)。为了分析异质性,我们采用了Galbraith图并进行了Cochrane卡方检验。
对24项试验(28个效应大小,n = 1603)的分析显示,食用益生菌和合生元后脂多糖水平显著降低,异质性高且证据确定性非常低(SMD(95%CI) = -0.54(-1.01,-0.07);I(%) = 94.4)。对13项试验的综合分析表明,食用益生菌和合生元后,闭合蛋白水平显著降低,异质性高且证据确定性中等(15个效应大小,n = 778)(SMD(95%CI) = -0.49(-0.79,-0.18);I(%) = 74.9)。补充益生元后,观察到脂多糖水平显著降低,从包括16项随机对照试验的数据中发现异质性高(n = 792;SMD(95%CI) = -0.88(-1.28,-0.47);P < 0.001;证据确定性高;I(%) = 85.7;P - 异质性 < 0.001)。
这项荟萃分析揭示了关于益生菌、合生元和益生元补充剂在缓解“肠漏”方面疗效的有前景的发现。